MAX BioPharma Announces Publication of Proof of Principle Regarding its Oxysterol Lead Drug Candidate, Oxy210 that Inhibits Fatty Liver and Fibrosis in a Humanized Mouse Model

LOS ANGELES: LOS ANGELES, Sept. 13, 2021 /PRNewswire/ -- Max BioPharma, Inc. (www.maxbiopharma.com) recently published an article that reported the efficacy of its anti-fibrotic and anti-inflammatory oxysterol lead compound, Oxy210, in the peer-reviewed journal, Endocrinology, Diabetes & Metabolism. (https://onlinelibrary.wiley.com/doi/full/10.1002/edm2.296) In a 16 week study conducted at UCLA, oral administration of...

Click to view original post